Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Anxiety disorders are a highly prevalent and disabling class of psychiatric disorders. This review focuses on new directions in neurobiological research and implications for the development of novel psychopharmacological treatments. Neuroanatomical and neuroimaging research in anxiety disorders has centered on the role of the amygdala, reciprocal connections between the amygdala and the prefrontal cortex, and, most recently, alterations in interoceptive processing by the anterior insula. Anxiety disorders are characterized by alterations in a diverse range of neurochemical systems, suggesting ample novel targets for drug therapies. Corticotropin‐releasing factor (CRF) concentrations are elevated in a subset of anxiety disorders, which suggests the potential utility of CRF receptor antagonists. Pharmacological blockade of the memory‐enhancing effects of stress hormones such as glucocorticoids and noradrenaline holds promise as a preventative approach for trauma‐related anxiety. The glutamatergic system has been largely overlooked as a potential pharmacological target, although convergent preclinical, neuroimaging, and early clinical findings suggest that glutamate receptor antagonists may have potent anxiolytic effects. Glutamatergic receptor agonists (e.g., D‐cycloserine) also have an emerging role in the treatment of anxiety as facilitators of fear extinction during concurrent behavioral interventions. The neuropeptides substance P, neuropeptide Y, oxytocin, orexin, and galanin are each implicated in anxiety pathways, and neuropeptide analogs or antagonists show early promise as anxiolytics in preclinical and/or clinical research. Each of these active areas of research holds promise for expanding and improving evidence‐based treatment options for individuals suffering with clinical anxiety. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
LeDoux, J. E. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.155 · Cited by 8,444
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI
Phan, K. L., Wager, T., Taylor, S. F., & Liberzon, I. (2002) · NeuroImage · doi:10.1006/nimg.2002.1087 · Cited by 3,502
Neural systems supporting interoceptive awareness
Critchley, H. D., Wiens, S., Rotshtein, P., Öhman, A., & Dolan, R. J. (2004) · Nature Neuroscience · doi:10.1038/nn1176 · Cited by 3,406 · cited 1×
“Although the bulk of anxiety disorder research to date has focused on the amygdala and its reciprocal connections to the prefrontal cortex, an emerging region of interest is the insula, known primarily for its central role in interoception [Critchley et al., 2004].”
BackgroundContributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior
Phelps, E. A., & LeDoux, J. E. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.025 · Cited by 3,203
Miller, G. E., Chen, E., & Zhou, E. S. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.1.25 · Cited by 2,467 · cited 1×
“…CRF in the cerebrospinal fluid [CSF; Bremner et al., 1997; Baker et al., 1999; Sautter et al., 2003], hypersuppression of cortisol in low dose (0.50 or 0.25 mg) dexamethasone-suppression tests [de Kloet et al., 2006], and, in a subset of studies, low 24-hr cortisol output [Miller et al., 2007].”
BackgroundInfluentialThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.195 · Cited by 1,605
Self-citationRauch, S. L., Shin, L. M., & Phelps, E. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.004 · Cited by 1,397
Is there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“It should be noted that glutamatergic modulation of pre- and post-synaptic receptors arises only in part from synaptic glutamate neurotransmission, and also is dependent on glutamate released via the cystine/glutamate transporter (system xc ) in glia [Nestler, 2005].”
BackgroundPaulus, M. P., & Stein, M. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.042 · Cited by 1,325
A role for lateral hypothalamic orexin neurons in reward seeking
Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005) · Nature · doi:10.1038/nature04071 · Cited by 1,311 · cited 1×
“Orexin neurons have been found to heavily innervate and excite neurons in the dopaminergic pathway from the ventral tegmental area to the nucleus accumbens [Harris et al., 2005; Scammell and Saper, 2005].”
BackgroundRauch, S. L., Whalen, P. J., Shin, L. M., McInerney, S. C., Macklin, M. L., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00828-3 · Cited by 1,111
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
The human amygdala and the emotional evaluation of sensory stimuli
Zald, D. H. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00248-5 · Cited by 1,062
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic
Ressler, K. J., & Mayberg, H. S. (2007) · Nature Neuroscience · doi:10.1038/nn1944 · Cited by 1,007
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol
Pitman, R. K., Sanders, K. M., Zusman, R. M., Healy, A. R., Cheema, F., Lasko, N. B., Cahill, L., & Orr, S. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01279-3 · Cited by 964
Increased Amygdala and Insula Activation During Emotion Processing in Anxiety-Prone Subjects
Stein, M. B., Simmons, A. N., Feinstein, J. S., & Paulus, M. P. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.318 · Cited by 851
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Vasopressin and Oxytocin Excite Distinct Neuronal Populations in the Central Amygdala
Huber, D., Veinante, P., & Stoop, R. (2005) · Science · doi:10.1126/science.1105636 · Cited by 804
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.5.624 · Cited by 721
Self-citationPrefrontal mechanisms in extinction of conditioned fear
Quirk, G. J., Garcia, R., & González-Lima, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.010 · Cited by 682 · cited 1×
“Reciprocal connectivity between the amygdala and prefrontal cortex is further implicated as a mechanism of fear extinction [Quirk et al., 2006].”
BackgroundMetabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Dębiec, J., & Ledoux, J. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.018 · Cited by 602
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“Similar results have now been obtained for patients with OCD [Kushner et al., 2007] and SAD [Hofmann et al., 2006] treated with truncated protocols (four sessions) of exposure therapy plus acute DCS; however, DCS did not improve results over placebo for OCD patients treated with a full course (12…”
ResultBaker, D. G., West, S. A., Nicholson, W. E., Ekhator, N. N., Kasckow, J. W., Hill, K. K., Bruce, A. B., Orth, D. N., & Geracioti, T. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.585 · Cited by 531
Scott, K. M., Bruffaerts, R., Tsang, A., Ormel, J., Alonso, J., Angermeyer, M. C., Benjet, C., Bromet, E., de Girolamo, G., de Graaf, R., et al. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.015 · Cited by 529
de Kloet, C. S., Vermetten, E., Geuze, E., Kavelaars, A., Heijnen, C. J., & Westenberg, H. G. M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.08.002 · Cited by 503
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma
Vaiva, G., Ducrocq, F., Jezequel, K., Averland, B., Lestavel, P., Brunet, A., & Marmar, C. R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00412-8 · Cited by 499 · cited 2×
“Preliminary proof-ofconcept studies have shown that acutely traumatized subjects treated with the beta adrenoreceptor antagonist propranolol have reduced incidence of PTSD symptoms at long-term follow-up [Pitman et al., 2002; Vaiva et al., 2003].”
BackgroundEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 2×
“…et al., 2002; Chhatwal et al., 2005; reviewed in Chhatwal and Ressler, 2007], mu-opioid receptor [McNally, 2005; McNally et al., 2005], and L-type calcium channel agonists [Cain et al., 2002] have a solid preclinical rationale for testing in patients undergoing CBT [see also Davis et al., 2006b].”
BackgroundEpinephrine enhancement of human memory consolidation: Interaction with arousal at encoding
Cahill, L., & Alkire, M. T. (2003) · Neurobiology of Learning and Memory · doi:10.1016/s1074-7427(02)00036-9 · Cited by 456 · cited 2×
“…for anxiety disorders such as PTSD. Cortisol [Buchanan and Lovallo, 2001; Abercrombie et al., 2003] and catecholamines such as noradrenaline [Cahill and Alkire, 2003] have been shown to promote long-term memory retention in humans, particularly for arousing stimuli, and may also contribute…”
BackgroundRauch, S. L., Savage, C. R., Alpert, N. M., Fischman, A. J., & Jenike, M. A. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00145-5 · Cited by 393 · cited 5×
“Consistent with this model, altered insular function has been demonstrated with brain imaging in patients with OCD, PTSD [Rauch et al., 1997], specific phobia [Rauch et al., 1997; Wright et al., 2003], SAD [Lorberbaum et al., 2004], GAD [Hoehn-Saric et al., 2004], and panic disorder [Malizia et al., 1998], as well as…”
BackgroundMethodInfluentialEnhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Advances in Understanding Neuroendocrine Alterations in PTSD and Their Therapeutic Implications
YEHUDA, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1364.012 · Cited by 335 · cited 1×
“Though there is currently no consensus as to the nature of HPA alterations in PTSD, an influential model emphasizing enhanced negative feedback inhibition of cortisol at the level of the pituitary has been proposed [Yehuda, 2006].”
BackgroundCortisol variation in humans affects memory for emotionally laden and neutral information.
Abercrombie, H. C., Kalin, N. H., Thurow, M. E., Rosenkranz, M. A., & Davidson, R. J. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.3.505 · Cited by 309 · cited 1×
“…and memory consolidation suggests a possible preventative strategy for anxiety disorders such as PTSD. Cortisol [Buchanan and Lovallo, 2001; Abercrombie et al., 2003] and catecholamines such as noradrenaline [Cahill and Alkire, 2003] have been shown to promote long-term memory retention in…”
BackgroundPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286
Adrenergic transmission facilitates extinction of conditional fear in mice
Cain, C. K., Blouin, A. M., & Barad, M. (2004) · Learning & Memory · doi:10.1101/lm.71504 · Cited by 215 · cited 2×
“In addition to partial agonists of NMDA glutamate receptors, extinction-enhancing drugs such as yohimbine [Cain et al., 2004], cannabinoid receptor 1 agonists [Marsicano et al.”
BackgroundD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200 · cited 1×
“…acute DCS; however, DCS did not improve results over placebo for OCD patients treated with a full course (12 weekly sessions) of exposure and response prevention [Storch et al., 2007], nor in a subclinical group of spider phobics treated with a single session of exposure [Guastella et al., 2007].”
BackgroundNeuroendocrine basis of social recognition
Winslow, J. T., & Insel, T. R. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.03.009 · Cited by 180
An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study
Mardikian, P. N., LaRowe, S. D., Hedden, S., Kalivas, P. W., & Malcolm, R. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.10.001 · Cited by 179
Heilig, M., Zachrisson, O., Thorsell, A., Ehnvall, A., Mottagui-Tabar, S., Sjögren, M., Åsberg, M., Ekman, R., Wahlestedt, C., & Ågren, H. (2004) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00101-8 · Cited by 177 · cited 1×
“To date, one CRF-1 receptor antagonist (R121919) has been tested in an open-label clinical trial for major depression [Zobel et al., 2000; Künzel et al., 2003; Held et al., 2004].”
BackgroundA randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear
Guastella, A. J., Dadds, M. R., Lovibond, P. F., Mitchell, P., & Richardson, R. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.006 · Cited by 164
Sautter, F. J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B., Myers, L., Johnson, J. E., Cerbone, A., & Malaspina, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00571-7 · Cited by 162
Cain, C. K., Blouin, A. M., & Barad, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09113.2002 · Cited by 130 · cited 2×
“…et al., 2002; Chhatwal et al., 2005; reviewed in Chhatwal and Ressler, 2007], mu-opioid receptor [McNally, 2005; McNally et al., 2005], and L-type calcium channel agonists [Cain et al., 2002] have a solid preclinical rationale for testing in patients undergoing CBT [see also Davis et al., 2006b].”
BackgroundA History of the Concept of Atypical Depression
Davidson, J. R. T., & Thase, M. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0207e03 · Cited by 119
Fossey, M. D., Lydiard, R. B., Ballenger, J. C., Laraia, M. T., Bissette, G., & Nemeroff, C. B. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00197-2 · Cited by 90
Intranasal oxytocin in obsessive-compulsive disorder
Epperson, C. N., McDougle, C. J., & Price, L. H. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)00120-5 · Cited by 88 · cited 7×
“Similar results have now been obtained for patients with OCD [Kushner et al., 2007] and SAD [Hofmann et al., 2006] treated with truncated protocols (four sessions) of exposure therapy plus acute DCS; however, DCS did not improve results over placebo for OCD patients treated with a full course (12 weekly sessions) of e…”
BackgroundMethodInfluential
Cited by
Joëls, M., & Baram, T. Z. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2632 · Cited by 1,521
Oxidative Stress and Anxiety: Relationship and Cellular Pathways
Bouayed, J., Rammal, H., & Soulimani, R. (2009) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.2.2.7944 · Cited by 517
Animal models of anxiety disorders and stress
Campos, A. C., Fogaca, M. V., Aguiar, D. C., & Guimaraes, F. S. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1139 · Cited by 471
Dynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Exploring the convergence of posttraumatic stress disorder and mild traumatic brain injury
Stein, M. B., & McAllister, T. W. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08101604 · Cited by 391
Metadata
- Authors
- Mathew, S. J., Price, R. B., & Charney, D. S.
- Venue
- American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Publisher
- Wiley
- Published
- 2008-04-22
- Volume
- 148C
- Issue
- 2
- Pages
- 89-98
- ISSN
- 1552-4868 (ISSN-L)
- 1552-4876
- OpenAlex
- W2088632365
- Cited by
- 168
- References
- 50
- FWCI
- 32.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.